Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | KIF11 | P52732 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | GRK2 | P25098 | 1/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30705784 | 0.98 | SMN1; SMN2 (0.54) | SMN1; SMN2HTTMAPTMEN1KMT2A | |
| SCHEMBL30343207 | 0.84 | KIF11 (0.65) | SMN1; SMN2HTTMAPTALDH1A1POLB | |
| SCHEMBL2367225 | 0.84 | KIF11 (0.65) | SMN1; SMN2HTTMAPTALDH1A1POLB | |
| SCHEMBL4095276 | 0.83 | POLB (0.44) | SMN1; SMN2HTTMAPTMEN1KMT2A | |
| SCHEMBL27775431 | 0.82 | GRIK1 (0.53) | SMN1; SMN2MEN1KMT2AALDH1A1POLB | |
| SCHEMBL3871775 | 0.82 | ALDH1A1 (0.52) | SMN1; SMN2HTTMEN1KMT2AALDH1A1 | |
| SCHEMBL15577575 | 0.82 | SMN1; SMN2 (0.57) | SMN1; SMN2HTTMAPTMEN1KMT2A | |
| SCHEMBL2755845 | 0.81 | MAPT (0.54) | SMN1; SMN2HTTMAPTMEN1KMT2A | |
| SCHEMBL1426650 | 0.81 | RAB9A (0.57) | SMN1; SMN2MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL29373841 | 0.81 | RAB9A (0.57) | SMN1; SMN2MAPTMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737830-A1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | The Procter and Gamble Company (US) | 2007-01-03 | — | — | EP | claimed |
| WO-2005105757-A1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-11-10 | — | — | WO | claimed |
| EP-1373224-B1 | NEW SPIROTRICYCLIC DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS | WARNER LAMBERT CO (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1801106-A2 | New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | disclosed |
| US-7214676-B2 | Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2007-05-08 | — | — | US | disclosed |
| US-20070049558-A1 | New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors | PFIZER INC. | 2007-03-01 | — | — | US | disclosed |
| US-20040214843-A1 | Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors | PFIZER INC | 2004-10-28 | — | — | US | disclosed |
| WO-2004087643-A1 | DEFORMYLASE INHIBITOR, PROCESS FOR PREPARING THE SAME, AND ANTIBACTERIAL COMPOSITION COMPRISING THE SAME | PROMEDITECH INC. (KR) | 2004-10-14 | — | — | WO | disclosed |
| EP-1373224-A1 | NEW SPIROTRICYCLIC DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS | Warner-Lambert Company LLC (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20020198198-A1 | Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors | WARNER-LAMBERT COMPANY LLC | 2002-12-26 | — | — | US | disclosed |
| WO-2002074754-A1 | NEW SPIROTRICYCLIC DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198198-A1 | Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors | PDE3A, PDE12, PDE5A | SMN1; SMN2 3562/4885HTT 4512/4885MAPT 4626/4885 |
| US-20040214843-A1 | Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors | PDE3A, PDE12, PDE5A | SMN1; SMN2 3562/4885HTT 4512/4885MAPT 4626/4885 |
| US-20070049558-A1 | New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors | PDE3A, PDE4A, PDE5A | SMN1; SMN2 3702/4885HTT 4610/4885MAPT 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.